News

Catch up on this week's highlights in retina.

Discover key insights from leading ophthalmology experts at the AAO meeting, featuring presentations, posters, and innovative discussions from October 17-20.

NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).

Additionally, the company also received Clinical Trial Authorisation (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Holz discusses advancements in retinal disease treatments at the EURETINA meeting, featuring gene therapy and innovative implants to enhance patient care.

A study reveals diverse ocular symptoms in Sjögren’s disease, linking eye features to oral and pain manifestations for personalized treatment strategies.

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.

Vizz is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults

As of October 1, 2025, the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J3403) to revakinagene taroretcel-lwey.

Behind the scenes of building impactful educational platforms in retina care

Lupin notes that the acquisition will help to strengthen the company by “integrating VISUfarma’s established commercial operations.”

The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.

Patient response focused on perceived vision-related quality of life outcomes, investigators said

Dr Miere presented the ACTOR study, illuminating vascular remodeling in patients with neovascular AMD, and the HERMES study, investigating perfusion changes in central retinal vein occlusion

Patricio Schlottmann highlights promising long-term results of faricimab for wet AMD, showcasing sustained visual gains and excellent safety in patients.

Miere discusses retinal studies on AMD and vein occlusion, highlighting imaging advancements and the future of machine learning in treatment predictions.

A study reveals atropine induces less myopic refraction than cyclopentolate in preschoolers, impacting premyopia diagnosis and intervention strategies.